Stock listing

BOATS:IMVT Immunovant, Inc. Stock

US listing (BOATS) of Immunovant, Inc. · home listing NASDAQ:IMVT

Follow Immunovant, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:IMVT

$31.77 USD -1.40 (-4.2%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:IMVT

Past year +39.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$31.62 – $32.77 USDNov 20, 2026
Volume
702,865 sharesNov 20, 2026
Market cap
$6.57B USDAt the close on Nov 20, 2026 · price × 206.9M shares outstanding
52-week range
$21.86 – $45.42 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$47.98M USDMedian day 1.24M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Immunovant, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IMVT · Home$31.77 USD-1.40 (-4.2%)702,865$32.07$32.77$31.62$33.17Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IMVT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$31.77-1.40-4.2%$32.07$32.77$31.62702,865
$33.17-0.04-0.1%$33.07$34.23$32.59907,602
$33.21-0.07-0.2%$33.17$33.82$32.45926,704
$33.28-0.90-2.6%$33.86$34.53$33.041,053,974
$34.18-0.87-2.5%$34.24$34.77$33.94864,692
$35.05-1.99-5.4%$36.92$36.92$34.861,182,848
$37.04+1.33+3.7%$35.77$37.59$35.521,712,162
$35.71+0.56+1.6%$35.15$35.96$34.831,644,281
$35.15+4.62+15.1%$33.00$35.61$32.813,978,245
$30.53+2.14+7.5%$28.73$30.60$28.342,658,239
$28.39-1.51-5.1%$29.78$29.83$28.121,119,632
$29.90+0.86+3.0%$29.82$29.93$28.501,109,836
$29.04+0.63+2.2%$28.70$29.48$28.421,079,583
$28.41-0.76-2.6%$29.32$29.64$28.381,268,029
$29.17-0.47-1.6%$29.49$29.78$28.761,165,416
$29.64+0.22+0.7%$29.56$30.07$29.331,399,285
$29.42+0.54+1.9%$28.50$29.47$28.441,241,925
$28.88+0.71+2.5%$28.06$28.96$28.011,057,999
$28.17-0.24-0.8%$28.46$28.50$27.631,195,295
$28.41-0.69-2.4%$28.93$28.93$28.14641,437
$29.10+0.72+2.5%$28.09$29.12$27.981,157,318
$28.38-0.21-0.7%$28.97$29.18$28.051,494,805
$28.59+0.97+3.5%$27.76$29.14$27.621,448,985
$27.62+0.89+3.3%$27.12$27.84$26.531,375,274
$26.73-0.78-2.8%$27.42$27.42$26.281,463,200
$27.51-0.39-1.4%$28.03$28.33$27.481,649,300
$27.90-0.81-2.8%$28.46$28.79$27.831,773,500
$28.71-0.77-2.6%$29.37$29.64$28.701,242,700
$29.48-0.99-3.2%$30.17$30.60$28.612,241,900
$30.47+0.21+0.7%$30.25$30.64$30.071,494,800
$30.26-1.78-5.6%$31.40$31.50$29.801,755,400
$32.04-0.07-0.2%$31.72$32.75$31.581,131,400
$32.11-1.14-3.4%$33.51$33.51$31.361,674,000
$33.25-0.37-1.1%$33.99$33.99$32.951,103,200
$33.62-0.03-0.1%$34.11$34.24$33.211,022,200
$33.65-0.13-0.4%$33.56$34.60$33.301,671,800
$33.78+0.32+1.0%$33.62$34.20$33.121,433,900
$33.46-0.03-0.1%$33.43$33.53$32.451,311,400
$33.49+0.19+0.6%$32.93$33.77$32.651,229,300
$33.30-0.70-2.1%$34.00$34.22$33.172,350,000
$34.00-0.54-1.6%$34.21$34.55$33.351,479,300
$34.54-2.75-7.4%$36.35$37.00$33.603,652,800
$37.29+0.11+0.3%$37.38$38.15$36.842,255,200
$37.18+0.23+0.6%$37.23$37.49$36.551,031,400
$36.95-0.70-1.9%$37.52$38.35$36.802,943,800
$37.65+1.27+3.5%$37.09$37.68$36.541,330,600
$36.38-0.27-0.7%$36.75$37.22$36.111,169,200
$36.65-1.01-2.7%$37.43$37.50$36.191,573,800
$37.66+0.30+0.8%$37.25$38.03$37.001,110,900
$37.36-0.74-1.9%$38.62$38.93$37.191,031,900
$38.10-0.65-1.7%$38.18$38.31$37.531,083,400
$38.75-0.82-2.1%$39.11$39.73$38.671,023,700
$39.57+0.32+0.8%$38.59$40.56$38.341,513,700
$39.25+0.13+0.3%$39.44$39.73$38.73765,600
$39.12-0.37-0.9%$39.48$39.48$38.641,235,400
$39.49-0.41-1.0%$40.15$40.96$38.611,331,000
$39.90-0.92-2.3%$40.60$41.37$39.201,585,500
$40.82-0.38-0.9%$40.96$41.28$39.911,391,700
$41.20-2.62-6.0%$43.27$43.38$41.091,082,500
$43.82-0.07-0.2%$43.60$43.95$43.14868,500
$43.89+0.39+0.9%$43.54$44.21$42.65852,400
$43.50+0.18+0.4%$43.79$44.50$43.271,346,827
$43.32-1.05-2.4%$44.00$44.04$43.201,189,318
$44.37+0.020.0%$44.85$45.12$44.08846,600
$44.35-0.61-1.4%$44.37$44.69$43.42954,400
Ticker
BOATS:IMVT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BOATS
Currency
USD

What changed lately

Latest news

All Immunovant, Inc. news

Immunovant, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
10 in the last 12 months · 90 in all · newest Nov 9, 2026 · oldest 2019
Calls
8 calls with a replay · 8 with a transcript · latest Nov 9, 2026
Decks
30 decks · latest November 2026

Where Immunovant, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IMVT · Home listingNASDAQUnited StatesUSD
BOATS:IMVT · This pageBOATSUnited StatesUSD

Valuation

EV/sales 825× against a median of 33.4×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$5.85B USD
P/E
Loss
EV/sales
825×
EV/EBITDA
Negative EBITDA
Price/book
10.0×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.46

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Immunovant, Inc. · NASDAQ:IMVTUS$6.57BUS$5.85Bn/a825×n/a10.0×n/a0.0×1.46
CG Oncology, Inc. · NASDAQ:CGONUS$7.10BUS$6.12Bn/a992×n/a7.2×n/a0.0×0.83
Cytokinetics, Incorporated · NASDAQ:CYTKUS$7.07BUS$6.36Bn/a56.2×n/an/a−686.6%n/a0.93
Axsome Therapeutics, Inc. · NASDAQ:AXSMUS$6.80BUS$6.68Bn/a7.7×n/a64.5×−18.2%1.8×0.69
Akeso, Inc. · HKEX:9926US$6.66BUS$6.04Bn/a13.5×n/a5.2×−36.4%0.6×n/a
Oruka Therapeutics, Inc. · NASDAQ:ORKAUS$6.50BUS$5.58Bn/an/an/a5.4×n/a0.0×1.30
ImmunityBio, Inc. · NASDAQ:IBRXUS$6.40BUS$6.10Bn/a33.4×n/an/a−607.8%n/a1.50
Kodiak Sciences Inc · NASDAQ:KODUS$6.35BUS$6.31Bn/an/an/a505×n/a3.7×1.58
Abivax SA · EURONEXT:ABVXUS$6.05BUS$5.60Bn/an/an/a15.1×n/a0.0×n/a
Scholar Rock Holding Corporation · NASDAQ:SRRKUS$5.87BUS$5.65Bn/a9,921×n/a34.8×n/a1.2×0.91
Arrowhead Pharmaceuticals, Inc. · NASDAQ:ARWRUS$5.85BUS$4.66Bn/a10.3×n/a116×−160.6%0.0×1.34
Median of the othersUS$6.45BUS$6.07B33.4×24.9×−160.6%0.3×1.12

Forecasts

11 strong buy · 2 buy · 4 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
48.31 USD · Analysts' mean
EPS, year to Mar 2027
-2.68 · 5 analysts

Team and board

Officers

OfficerRole
Eric VenkerChief Executive Officer
Tiago GirãoChief Financial Officer
Melanie GloriaChief Operating Officer
Christopher Van TuylChief Legal Officer and Corporate Secretary
Chedvi Levin-SisterVice President of Finance
Christine BlodgettSenior Vice President of Human Resources
Dawn GardnerVice President, Program Management
Elena GrigoryevaSenior Vice President, Head of Clinical Development
Harry BerlangaVP, CMC & Distribution Quality
Philip TedeschiVice President, Translational Sciences and Clinical Laboratories
Rod SaponjicVice President of Clinical Operations
Sheetal PatelSenior Vice President, Clinical Development
Frank TortiExecutive Chairman
Jay S. StoutChief Technology Officer
Ruby GrewalChief Strategy Officer

Board

DirectorRole
Frank TortiExecutive Chairman
Andrew FromkinMember of the Board of Directors
Atul PandeMember of the Board of Directors
Douglas HughesMember of the Board of Directors
Eric VenkerChief Executive Officer
Jake BauerBoard Member
Robert SusmanMember of the Board of Directors

Events

Calls

CallWhenStatus
Immunovant (NASDAQ:IMVT) Q2 2026 Earnings CallMon, Nov 09, 2026 · 8:00 AM ETReplay
Immunovant (NASDAQ:IMVT) Q1 2026 Earnings CallThu, Aug 06, 2026 · 8:00 AM ETReplay
Immunovant (NASDAQ:IMVT) Q3 2025 Earnings CallFri, Feb 06, 2026 · 8:00 AM ETReplay
Immunovant (NASDAQ:IMVT) Q2 2025 Earnings CallMon, Nov 10, 2025 · 8:00 AM ETReplay
Immunovant (NASDAQ:IMVT) Q1 2025 Earnings CallMon, Aug 11, 2025 · 8:00 AM ETReplay
Immunovant (NASDAQ:IMVT) Q4 2024 Earnings CallThu, May 29, 2025 · 8:00 AM ETReplay
Immunovant (NASDAQ:IMVT) Q4 2022 Earnings CallWed, Jun 08, 2022 · 8:00 AM ETReplay
Immunovant (NASDAQ:IMVT) Q2 2022 Earnings CallMon, Aug 09, 2021 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q2 2027Nov 9, 2026 · Before open+15.1%
Q1 2027Aug 6, 2026 · Before open+1.2%
Q4 2026May 20, 2026 · Before open+35.3%
Q3 2026Feb 6, 2026 · Before open+12.4%
Q2 2026Nov 10, 2025 · Before open+0.1%
Q1 2026Aug 11, 2025 · Before open−4.5%
Q4 2025May 29, 2025+5.3%
Q3 2025Feb 6, 2025 · Before open−9.6%
Q2 2025Nov 7, 2024 · Before open−4.7%
Q1 2025Aug 6, 2024 · After close−3.1%
All 20 quarters
QuarterResultsShare move
Q4 2024May 29, 2024 · After close−10.7%
Q3 2024Feb 12, 2024 · Before open+3.4%
Q2 2024Nov 9, 2023 · Before open−6.2%
Q1 2024Aug 10, 2023 · Before open+6.7%
Q4 2023May 22, 2023 · Before open+12.0%
Q3 2023Feb 3, 2023 · Before open−3.0%
Q2 2023Nov 4, 2022 · Before open+1.1%
Q1 2023Aug 5, 2022 · Before open+8.7%
Q4 2022Jun 8, 2022 · Before open−8.2%
Q3 2022Feb 4, 2022 · Before open−1.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck68 slidesNovember 2026
Investor Presentation (September 2026)Investor deck62 slidesSeptember 2026
Q1 2026 Earnings PresentationEarnings69 slidesAug 6, 2026
Technical Presentation (September 2025)Technical23 slidesSep 3, 2025
Corporate Update (April 2025)Corporate update27 slidesApr 21, 2025
Corporate Update (March 2025)Corporate update34 slidesMar 19, 2025
2025 J.P. Morgan Healthcare ConferenceConference21 slidesJan 14, 2025
Investor Day (2025)Investor day56 slides2025
Corporate Update (November 2024)Corporate update29 slidesNov 7, 2024
Corporate Update (September 2024)Corporate update32 slidesSep 9, 2024
All 30 decks
DeckKindSlidesDate
42nd Annual J.P. Morgan Healthcare Conference (January 2024)Conference23 slidesJan 9, 2024
Corporate Update (November 2023)Corporate update27 slidesNov 28, 2023
Technical Presentation (September 2023)Technical23 slidesSep 26, 2023
Corporate Update (May 2023)Corporate update7 slidesMay 22, 2023
Investor Presentation (March 2023)Investor deck56 slidesMar 27, 2023
Investor Presentation (January 2023)Investor deck52 slidesJan 9, 2023
LifeSci Capital Fireside Chat (December 2022)Conference32 slidesDec 8, 2022
Corporate Update (September 2022)Corporate update21 slidesSep 28, 2022
Corporate Update (September 2022)Corporate update36 slidesSep 7, 2022
Investor Presentation (June 2022)Investor deck14 slidesJun 8, 2022
Investor Day (March 2022)Investor day86 slidesMar 30, 2022
Corporate Update (January 2022)Corporate update14 slidesJan 5, 2022
Stifel 2021 Virtual Healthcare ConferenceConference9 slidesNov 17, 2021
Investor Day (September 2021)Investor day7 slidesSep 27, 2021
Investor Presentation (September 2021)Investor deck7 slidesSep 15, 2021
Corporate Update (June 2021)Corporate update17 slidesJun 1, 2021
Corporate Update (August 2020)Corporate update15 slidesAug 25, 2020
Investor Presentation (March 2020)Investor deck38 slidesMar 30, 2020
Health Sciences Acquisitions — SPAC Merger (November 2019)SPAC merger44 slidesNov 14, 2019
Health Sciences Acquisitions — SPAC Merger (October 2019)SPAC merger43 slidesOct 2, 2019

Open Decks

Financings

RaiseDate
Public offering of common stock
Announced: about US$550M · US$21 a share · Leerink Partners
Dealers: Leerink Partners (lead)
Buyers: Roivant Sciences Ltd.
Insiders: Roivant Sciences Ltd., the controlling stockholder, has agreed to purchase shares in the offering
Use of proceeds: Fund operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 in Graves’ Disease
Dec 11, 2025
Private placement of shares of common stock
Announced: about US$450M · US$20 a share
Buyers: Roivant
Use of proceeds: Advancement of its development pipeline, working capital and other general corporate purposes
Jan 13, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Health Sciences Acquisitions Corp, a blank check company (SPAC). Priced at US$10.00 a unit on May 9, 2019.

Price
US$10.00 a unit
Units offered
10,000,000 units
Offering size
US$100 million
Underwriters' option
Up to 1,500,000 more units
Listing
HSACU on the Nasdaq Capital Market
Underwriters
Chardan, UBS Investment Bank · In the order on the cover
Units delivered
On or about May 14, 2019

Steps

StepWhen
Draft sent to the SEC in confidenceJan 23, 2019
Filed publiclyApr 16, 2019
Amended twiceNewest May 3, 2019
Shares registered with an exchangeMay 9, 2019
Declared effective by the SECMay 9, 2019
Final prospectus, with the priceMay 10, 2019

Open IPO · From the cover of the final prospectus (424B4) filed May 10, 2019

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018
Revenue0000000
Cost of revenue409.0K377.0K231.0K1.32M1.23M998.0K21.0K
Gross profit-409.0K-377.0K-231.0K-1.32M-1.23M-998.0K-21.0K
Research and development456.7M360.9M212.9M160.3M101.8M68.6M47.9M25.7M135.3M
Selling, general and administrative76.2M77.2M57.3M48.0M54.2M39.5M18.2M2.69M1.48M
Operating income-532.9M-438.2M-270.2M-208.3M-156.0M-108.1M-59.7M-450-450-136.7M
Depreciation and amortization409.0K377.0K231.0K193.0K126.0K65.0K21.0K10.0K136.7M
EBITDA-532.5M-437.8M-270.0M-208.1M-155.9M-108.1M-59.7M9.55K0
Interest expense49.9M12.5M655.0K0625.0K000
Income before tax-505.4M-412.9M-258.8M-211.0M-156.8M-107.8M-66.3M-28.6M-450-136.7M
Income tax215.0K891.0K567.0K9.00K-84.0K-358.0K97.0K19.0K
Net income-505.6M-413.8M-259.3M-211.0M-156.7M-107.4M-66.4M-28.6M-450-136.7M
Earnings per share, basic-2.77-2.73-1.88-1.71-1.43-1.22-1.54-1.29-13.67
Earnings per share, diluted-2.77-2.73-1.88-1.71-1.43-1.22-1.54-1.29

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents902.1M714.0M635.4M376.5M493.8M400.1M100.6M6.99M
Receivables1.13M2.08M5.34M700.0K12.2M596.0K3.04M2.96M
Inventory-24.9M000
Current assets948.8M767.7M665.8M404.3M512.9M409.0M109.1M12.6M113.2K
Property, plant and equipment443.0K844.0K462.0K333.0K330.0K201.0K65.0K54.0K
Total assets957.0M776.2M666.4M405.8M515.6M412.5M109.4M13.8M113.2K
Accounts payable7.54M17.7M7.16M1.35M18.6M2.43M1.19M206.0K1.14M
Current liabilities104.4M68.8M48.6M43.3M44.5M18.8M15.3M300.4K1.61M
Total debt72.0K98.0K138.0K1.22M2.36M3.42M3.19M300.0K
Total liabilities104.4M68.8M48.6M43.3M45.7M21.0M15.3M6.49M1.61M
Shareholders' equity852.6M707.4M617.8M362.5M469.8M391.5M94.1M7.34M-1.50M
Shares outstanding203.9M170.1M145.6M130.3M116.5M98.0M54.7M38.6M10.0M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018
Cash from operations-407.3M-375.9M-214.2M-188.2M-106.1M-83.3M-53.4M-28.5M-128.3M
Capital spending-8.00K-759.0K-360.0K-197.0K-254.0K-210.0K-31.0K-52.0K0-52.0K
Free cash flow-407.3M-376.6M-214.6M-188.4M-106.4M-83.5M-53.4M-28.6M-128.3M
Cash from investing-8.00K-759.0K-360.0K-197.0K-254.0K-210.0K-31.0K-52.0K-52.0K
Cash from financing595.8M454.5M472.4M70.9M200.1M383.1M147.0M35.6M325.0K128.3M
Share buybacks70.9M200.0M385.2M1.00K25.0K25.0K
Change in cash188.1M78.6M258.8M-117.3M93.7M299.6M93.6M6.99M325.0K6.99M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 12, 2026Insider tradeSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
S-3ASR · Registration statementNov 9, 2026Offer documentSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
4 · Change in ownershipOct 23, 2026Insider tradeSEC
4 · Change in ownershipOct 9, 2026Insider tradeSEC
4 · Change in ownershipOct 9, 2026Insider tradeSEC
4 · Change in ownershipOct 9, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
8-K · Current reportSep 3, 2026Meeting outcomeSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipJul 24, 2026Insider tradeSEC
4 · Change in ownershipJul 24, 2026Insider tradeSEC
4 · Change in ownershipJul 24, 2026Insider tradeSEC
ARS · Annual report to shareholdersJul 22, 2026Annual reportSEC
DEFA14A · Additional proxy materialJul 22, 2026Meeting noticeSEC
DEF 14A · Proxy statementJul 22, 2026Meeting noticeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
144 · Notice of proposed saleJun 15, 2026Other filingsSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
144 · Notice of proposed saleMay 28, 2026Other filingsSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
144 · Notice of proposed saleMay 20, 2026Other filingsSEC
10-K · Annual reportMay 20, 2026Annual reportSEC
8-K · Current reportMay 20, 2026ResultsSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
4 · Change in ownershipApr 24, 2026Insider tradeSEC
4 · Change in ownershipApr 24, 2026Insider tradeSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 10, 2026Other filingsSEC
10-Q · Quarterly reportFeb 6, 2026Quarterly reportSEC
8-K · Current reportFeb 6, 2026ResultsSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 12, 2025Big-stake noticeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
8-K · Current reportDec 12, 2025Current reportSEC
424B5 · ProspectusDec 12, 2025Offer documentSEC
8-K · Current reportDec 11, 2025Current reportSEC
FWP · Free writing prospectusDec 10, 2025Offer documentSEC
4 · Change in ownershipDec 3, 2025Insider tradeSEC
4 · Change in ownershipDec 3, 2025Insider tradeSEC
144 · Notice of proposed saleDec 1, 2025Other filingsSEC
144 · Notice of proposed saleDec 1, 2025Other filingsSEC
144 · Notice of proposed saleNov 26, 2025Other filingsSEC
144 · Notice of proposed saleNov 25, 2025Other filingsSEC
4 · Change in ownershipNov 21, 2025Insider tradeSEC
8-K · Current reportNov 21, 2025Management or board changeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
8-K · Current reportSep 3, 2025Current reportSEC
8-K · Current reportAug 28, 2025Meeting outcomeSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
8-K · Current reportAug 11, 2025ResultsSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
8-K · Current reportJul 29, 2025Management or board changeSEC
4 · Change in ownershipJul 25, 2025Insider tradeSEC
4 · Change in ownershipJul 25, 2025Insider tradeSEC
4 · Change in ownershipJul 11, 2025Insider tradeSEC
4 · Change in ownershipJul 11, 2025Insider tradeSEC
ARS · Annual report to shareholdersJul 9, 2025Annual reportSEC
DEFA14A · Additional proxy materialJul 9, 2025Meeting noticeSEC
DEF 14A · Proxy statementJul 9, 2025Meeting noticeSEC
144 · Notice of proposed saleJun 25, 2025Other filingsSEC
144 · Notice of proposed saleJun 13, 2025Other filingsSEC
144 · Notice of proposed saleJun 3, 2025Other filingsSEC
10-K · Annual reportMay 29, 2025Annual reportSEC
8-K · Current reportMay 29, 2025ResultsSEC
144 · Notice of proposed saleMay 21, 2025Other filingsSEC
144 · Notice of proposed saleMay 19, 2025Other filingsSEC
4 · Change in ownershipMay 5, 2025Insider tradeSEC
4 · Change in ownershipMay 5, 2025Insider tradeSEC
4 · Change in ownershipMay 5, 2025Insider tradeSEC
S-8 · Registration statement for employee plansApr 30, 2025Offer documentSEC
3 · Initial statement of ownershipApr 28, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 28, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 28, 2025Insider tradeSEC
4 · Change in ownershipApr 25, 2025Insider tradeSEC
4 · Change in ownershipApr 25, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 21, 2025Big-stake noticeSEC
8-K · Current reportApr 21, 2025Management or board changeSEC
4 · Change in ownershipApr 17, 2025Insider tradeSEC
4 · Change in ownershipApr 17, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMar 26, 2025Big-stake noticeSEC
8-K · Current reportMar 19, 2025Current reportSEC
4 · Change in ownershipMar 11, 2025Insider tradeSEC
144 · Notice of proposed saleMar 7, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 7, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 14, 2025Other filingsSEC
144 · Notice of proposed saleFeb 11, 2025Other filingsSEC
10-Q · Quarterly reportFeb 6, 2025Quarterly reportSEC
8-K · Current reportFeb 6, 2025ResultsSEC
8-K · Current reportJan 24, 2025Current reportSEC
424B3 · ProspectusJan 24, 2025Offer documentSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
DJan 21, 2025Other filingsSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 15, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 15, 2025Big-stake noticeSEC
8-K · Current reportJan 14, 2025Current reportSEC
8-K · Current reportJan 13, 2025Material contractSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
3 · Initial statement of ownershipDec 18, 2024Insider tradeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
144 · Notice of proposed saleDec 2, 2024Other filingsSEC
144 · Notice of proposed saleDec 2, 2024Other filingsSEC
4 · Change in ownershipNov 22, 2024Insider tradeSEC
4 · Change in ownershipNov 22, 2024Insider tradeSEC
4 · Change in ownershipNov 22, 2024Insider tradeSEC
4 · Change in ownershipNov 22, 2024Insider tradeSEC
4 · Change in ownershipNov 20, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 20, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
4 · Change in ownershipOct 25, 2024Insider tradeSEC
4 · Change in ownershipOct 25, 2024Insider tradeSEC
4 · Change in ownershipOct 25, 2024Insider tradeSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
8-K · Current reportSep 9, 2024Current reportSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
8-K · Current reportAug 13, 2024Meeting outcomeSEC

This page holds 200 of 653 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Immunovant, Inc.’s releases · as of Nov 3, 2026

Common shares
206,947,758
Fully diluted
206,947,758

Fully diluted

LineSharesAs of
Common shares206,947,758Nov 3, 2026

Share count over time

CountShares
Nov 3, 2026206,947,758
Sep 30, 2026206,785,540

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Fidelity15.7M7.6%US$530MSep 30, 2026
Deep Track Capital, LP9.16M4.4%US$309MSep 30, 2026
Vanguard9.07M4.4%US$307MSep 30, 2026
BlackRock7.43M3.6%US$251MSep 30, 2026
Farallon Capital Management, L.L.C.6.47M3.1%US$219MSep 30, 2026
Morgan Stanley5.68M2.7%US$192MSep 30, 2026
Two Seas Capital LP4.61M2.2%US$156MSep 30, 2026
TCG Crossover Management, LLC4.46M2.2%US$151MSep 30, 2026
State Street4.2M2.0%US$142MSep 30, 2026
T. Rowe Price3.28M1.6%US$111MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Rtw Investments, LP3.18M1.5%US$107MSep 30, 2026
Jennison Associates LLC2.92M1.4%US$98.5MSep 30, 2026
Baker Bros. Advisors LP2.77M1.3%US$93.6MSep 30, 2026
Geode Capital2.25M1.1%US$76MSep 30, 2026
ADAR1 Capital Management, LLC2.12M1.0%US$71.5MSep 30, 2026
Woodline Partners LP1.98M0.95%US$66.7MSep 30, 2026
Armistice Capital, LLC1.74M0.84%US$58.7MSep 30, 2026
Goldman Sachs1.6M0.77%US$54.1MSep 30, 2026
Alpine Global Management, LLC1.37M0.66%US$46.3MSep 30, 2026
Bank of America1.35M0.65%US$45.7MSep 30, 2026
D. E. Shaw & Co., Inc.1.11M0.54%US$37.4MSep 30, 2026
Schwab1.02M0.49%US$34.6MSep 30, 2026
Susquehanna1000K0.48%US$33.8MSep 30, 2026
abrdn879K0.42%US$29.7MSep 30, 2026
UBS868K0.42%US$29.3MSep 30, 2026
Northern Trust795K0.38%US$26.9MSep 30, 2026
Renaissance Technologies780K0.38%US$26.3MSep 30, 2026
BNY655K0.32%US$22.1MSep 30, 2026
Silverarc Capital Management, LLC624K0.30%US$21.1MSep 30, 2026
Fisher Asset Management, LLC546K0.26%US$18.4MSep 30, 2026
Perceptive Advisors LLC519K0.25%US$17.5MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.418K0.20%US$14.1MSep 30, 2026
Jump Financial, LLC369K0.18%US$12.5MSep 30, 2026
Pictet Asset Management Holding SA359K0.17%US$12.1MSep 30, 2026
BNP Paribas358K0.17%US$12.1MSep 30, 2026
Marshall Wace, LLP343K0.17%US$11.6MSep 30, 2026
Nuveen288K0.14%US$9.73MSep 30, 2026
Tetragon Partners GP Ltd275K0.13%US$9.3MSep 30, 2026
Millennium257K0.12%US$8.67MSep 30, 2026
Squarepoint Ops LLC245K0.12%US$8.29MSep 30, 2026
Superstring Capital Management LP222K0.11%US$7.5MSep 30, 2026
Qube Research & Technologies Ltd220K0.11%US$7.42MSep 30, 2026
HighVista Strategies LLC206K0.10%US$6.96MSep 30, 2026
Stempoint Capital LP201K0.10%US$6.8MSep 30, 2026
Atom Investors LP177K0.09%US$5.97MSep 30, 2026
Group One Trading LLC163K0.08%US$5.5MSep 30, 2026
Granahan Investment Management, LLC149K0.07%US$5.03MSep 30, 2026
Erste Asset Management GmbH145K0.07%US$4.83MSep 30, 2026
DWS137K0.07%US$4.64MSep 30, 2026
DAFNA Capital Management LLC136K0.07%US$4.58MSep 30, 2026

This page holds 50 of 222 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Fidelity Growth Company Fund5.1M2.5%US$170MMay 31, 2026
Vanguard Total Stock Market Index Fund2.6M1.3%US$100MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2.58M1.2%US$99.3MJun 30, 2026
iShares Russell 2000 ETF2.19M1.1%US$84.4MJun 30, 2026
Vanguard Small-Cap Index Fund1.88M0.91%US$72.5MJun 30, 2026
Fidelity Growth Company K6 Fund1.4M0.68%US$46.7MMay 31, 2026
Fidelity Series Growth Company Fund1.11M0.54%US$37.1MMay 31, 2026
Vanguard Small-Cap Growth Index Fund1.09M0.52%US$41.9MJun 30, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.991K0.48%US$38.2MJun 30, 2026
PGIM Jennison Small Company Fund982K0.47%US$37.8MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Small Cap Index Fund933K0.45%US$36MJul 31, 2026
Vanguard Extended Market Index Fund888K0.43%US$34.2MJun 30, 2026
iShares Russell 2000 Growth ETF788K0.38%US$30.3MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund642K0.31%US$24.7MJun 30, 2026
iShares Biotechnology ETF574K0.28%US$22.1MJun 30, 2026
Fidelity Contrafund550K0.27%US$21.2MJun 30, 2026
T. Rowe Price Institutional Small-Cap Stock Fund536K0.26%US$20.7MJun 30, 2026
Vanguard Russell 2000 Index Fund419K0.20%US$13.9MMay 31, 2026
Fidelity Extended Market Index Fund399K0.19%US$13.3MMay 31, 2026
T. Rowe Price New Horizons Fund, Inc.376K0.18%US$14.5MJun 30, 2026
Schwab U.S. Small-Cap ETF371K0.18%US$12.4MMay 31, 2026
PGIM Jennison Health Sciences Fund278K0.13%US$9.25MMay 29, 2026
Vanguard Explorer Fund274K0.13%US$10.6MJul 31, 2026
Select Biotechnology Portfolio272K0.13%US$9.06MMay 31, 2026
Inception Portfolio252K0.12%US$9.71MJun 30, 2026
Nuveen Quant Small Cap Equity Fund252K0.12%US$9.73MJul 31, 2026
Vanguard Health Care Index Fund242K0.12%US$8.07MMay 31, 2026
Morgan Stanley Discovery Portfolio234K0.11%US$9.01MJun 30, 2026
Morgan Stanley Insight Fund230K0.11%US$8.87MJun 30, 2026
EQ/Morgan Stanley Small Cap Growth Portfolio211K0.10%US$8.13MJun 30, 2026
Schwab Small-Cap Index Fund207K0.10%US$7.98MJul 31, 2026
Master Small Cap Index Series156K0.08%US$6.03MJun 30, 2026
Discovery Portfolio156K0.08%US$5.99MJun 30, 2026
Fidelity Total Market Index Fund151K0.07%US$5.04MMay 31, 2026
VIP Contrafund Portfolio141K0.07%US$5.45MJun 30, 2026
Fidelity Advisor New Insights Fund126K0.06%US$4.85MJun 30, 2026
Fidelity Nasdaq Composite Index Fund125K0.06%US$4.17MMay 31, 2026
Nomura Healthcare Fund122K0.06%US$4.7MJun 30, 2026
Fidelity Series Total Market Index Fund118K0.06%US$3.92MMay 31, 2026
Fidelity Contrafund K6118K0.06%US$4.53MJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF116K0.06%US$4.46MJun 30, 2026
Nuveen Small Cap Blend Index Fund113K0.05%US$4.36MJul 31, 2026
PGIM Jennison Blend Fund99,5290.05%US$3.31MMay 29, 2026
EQ/2000 Managed Volatility Portfolio92,7130.04%US$3.57MJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares87,3180.04%US$3.37MJul 31, 2026
Fidelity Small Cap Growth Index Fund79,9560.04%US$3.08MJun 30, 2026
Vanguard Russell 2000 Growth Index Fund76,4420.04%US$2.55MMay 31, 2026
Nuveen Small Cap Value Fund72,2200.03%US$2.79MJul 31, 2026
T.Rowe Price Small Cap Growth Portfolio71,6550.03%US$2.76MJun 30, 2026
Vanguard Total World Stock Index Fund67,3190.03%US$2.6MJul 31, 2026

This page holds 50 of 201 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Pande Atul
Director
Sale3,000USD 36.00US$108KNov 11, 2026
Girao Tiago
Officer: Chief Financial Officer
Sale6,606USD 28.50US$188KOct 28, 2026
Stout Jay S
Officer: Chief Technology Officer
Sale2,595USD 28.94US$75,099Oct 21, 2026
Stout Jay S
Officer: Chief Technology Officer
Sale2,213USD 32.06US$70,949Oct 7, 2026
Stout Jay S
Officer: Chief Technology Officer
Sale1,596USD 32.06US$51,168Oct 7, 2026
Gloria Melanie
Officer: Chief Operating Officer
Sale2,241USD 32.06US$71,846Oct 7, 2026
Van Tuyl Christopher
Officer: Chief Legal Officer
Sale1,327USD 32.06US$42,544Oct 7, 2026
Venker Eric
Director, Officer: Chief Executive Officer
Sale3,506USD 34.11US$120KOct 2, 2026
Van Tuyl Christopher
Officer: Chief Legal Officer
Sale2,846USD 36.36US$103KSep 23, 2026
Pande Atul
Director
Sale1,500USD 43.27US$64,905Aug 28, 2026
All 48 trades
TradeTradeSharesPriceValueDate
Gloria Melanie
Officer: Chief Operating Officer
Sale3,056USD 44.16US$135KAug 20, 2026
Pande Atul
Director
Sale1,500USD 39.80US$59,700Jul 24, 2026
Girao Tiago
Officer: Chief Financial Officer
Sale6,798USD 38.69US$263KJul 23, 2026
Stout Jay S
Officer: Chief Technology Officer
Sale2,857USD 38.69US$111KJul 23, 2026
Stout Jay S
Officer: Chief Technology Officer
Sale1,906USD 39.53US$75,344Jul 8, 2026
Stout Jay S
Officer: Chief Technology Officer
Sale105USD 39.99US$4,199Jul 8, 2026
Stout Jay S
Officer: Chief Technology Officer
Sale1,399USD 39.53US$55,302Jul 8, 2026
Stout Jay S
Officer: Chief Technology Officer
Sale77USD 39.99US$3,079Jul 8, 2026
Van Tuyl Christopher
Officer: Chief Legal Officer
Sale1,143USD 39.53US$45,183Jul 8, 2026
Van Tuyl Christopher
Officer: Chief Legal Officer
Sale63USD 39.99US$2,519Jul 8, 2026
Gloria Melanie
Officer: Chief Operating Officer
Sale1,930USD 39.53US$76,293Jul 8, 2026
Gloria Melanie
Officer: Chief Operating Officer
Sale106USD 39.99US$4,239Jul 8, 2026
Venker Eric
Director, Officer: Chief Executive Officer
Sale3,092USD 38.48US$119KJul 2, 2026
Pande Atul
Director
Sale1,500USD 38.01US$57,015Jun 26, 2026
Girao Tiago
Officer: Chief Financial Officer
Sale10,000USD 38.46US$385KJun 26, 2026
Van Tuyl Christopher
Officer: Chief Legal Officer
Sale14,982USD 38.19US$572KJun 26, 2026
Van Tuyl Christopher
Officer: Chief Legal Officer
Sale2,842USD 38.96US$111KJun 26, 2026
Stout Jay S
Officer: Chief Technology Officer
Sale33,277USD 38.18US$1.27MJun 26, 2026
Stout Jay S
Officer: Chief Technology Officer
Sale6,723USD 38.94US$262KJun 26, 2026
Gloria Melanie
Officer: Chief Operating Officer
Sale14,748USD 38.18US$563KJun 26, 2026
Gloria Melanie
Officer: Chief Operating Officer
Sale2,966USD 38.95US$116KJun 26, 2026
Van Tuyl Christopher
Officer: Chief Legal Officer
Sale2,634USD 35.39US$93,217Jun 18, 2026
Pande Atul
Director
Sale1,500USD 34.02US$51,030Jun 15, 2026
Fromkin Andrew J.
Director
Sale11,483USD 32.64US$375KMay 28, 2026
Fromkin Andrew J.
Director
Sale210,468USD 33.56US$7.06MMay 28, 2026
Gloria Melanie
Officer: Chief Operating Officer
Sale249USD 30.41US$7,572May 20, 2026
Gloria Melanie
Officer: Chief Operating Officer
Sale1,168USD 32.15US$37,551May 20, 2026
Gloria Melanie
Officer: Chief Operating Officer
Sale1,698USD 32.95US$55,949May 20, 2026
Pande Atul
Director
Sale6,000USD 32.00US$192KMay 20, 2026
Susman Robert Graham
Director
Sale2,502USD 27.17US$67,979May 1, 2026
Stout Jay S
Officer: Chief Technology Officer
Sale2,754USD 29.62US$81,573Apr 23, 2026
Girao Tiago
Officer: Chief Financial Officer
Sale25,760USD 29.62US$763KApr 23, 2026
Stout Jay S
Officer: Chief Technology Officer
Sale8,614USD 24.83US$214KApr 8, 2026
Stout Jay S
Officer: Chief Technology Officer
Sale1,518USD 24.83US$37,692Apr 8, 2026
Van Tuyl Christopher
Officer: Chief Legal Officer
Sale5,165USD 24.83US$128KApr 8, 2026
Gloria Melanie
Officer: Chief Operating Officer
Sale8,722USD 24.83US$217KApr 8, 2026
Venker Eric
Director, Officer: Chief Executive Officer
Sale12,820USD 24.04US$308KApr 2, 2026
Venker Eric
Director, Officer: Chief Executive Officer
Sale1,409USD 24.60US$34,661Apr 2, 2026

Big stakes

StakeStakeSharesDateFiling
Roivant Sciences Ltd.55.90%113MDec 12, 2025Schedule 13D
FMR LLC8.40%14.7MSep 30, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Myrtle S Potter
Other companies: Ginkgo Bioworks Holdings, Inc. (Director · Since at least Jun 13, 2024); Guardant Health, Inc. (Director · Since at least Oct 15, 2021); Arbutus Biopharma Corporation (Director · Oct 18, 2018 – Aug 17, 2019 · Past); Sio Gene Therapies Inc (Director · Sep 26, 2018 – Apr 15, 2019 · Past); Urovant Sciences Ltd (Director · Sep 26, 2018 – Mar 29, 2021 · Past); Myovant Sciences Ltd (Director · Sep 20, 2018 – Mar 10, 2023 · Past); Axsome Therapeutics, Inc. (Director · Jun 16, 2017 – Jun 7, 2019 · Past); Insmed Incorporated (Director · Dec 11, 2014 – May 15, 2018 · Past); Everyday Health Inc (Director · Mar 27, 2014 – Dec 3, 2016 · Past); Rite Aid Corporation (Director · Nov 29, 2013 – Oct 3, 2017 · Past)
Director · Dec 18, 2019 – Dec 18, 2019 · Past
Pedro P Granadillo
Other companies: Rocket Pharmaceuticals, Inc. (Director · Since at least Jan 4, 2018); Orchestra BioMed Holdings, Inc. (Director · Aug 3, 2020 – Aug 3, 2020 · Past); NPS Pharmaceuticals Inc (Director · Nov 17, 2010 – Feb 21, 2015 · Past); Dendreon Corp (Director · Oct 7, 2009 – Jan 3, 2014 · Past); Capricor Therapeutics, Inc. (Director · Oct 16, 2007 – May 10, 2011 · Past); Haemonetics Corporation (Director · May 5, 2006 – Nov 8, 2018 · Past); First Indiana Corp (Director · Jan 3, 2006 – Jan 2, 2008 · Past)
Director · May 9, 2019 – May 9, 2019 · Past
Eric Venker
Other companies: Roivant Sciences Ltd. (Roivant President and Immunovant CEO · Since at least Oct 1, 2021); Arbutus Biopharma Corporation (Director · Feb 18, 2020 – Feb 18, 2020 · Past); Sio Gene Therapies Inc (Director · Feb 17, 2020 – Feb 17, 2020 · Past)
Chief Executive Officer · Since at least Feb 18, 2020
Sukumar Nagendran
Other companies: Taysha Gene Therapies, Inc. (Director · Since at least Sep 23, 2020); Solid Biosciences Inc. (President, Head of Research & Development, Taysha Gene Therapies · Since at least Sep 12, 2018); AveXis Inc (Sr. VP & Chief Medical Officer · Feb 10, 2016 – May 15, 2018 · Past)
Director · May 9, 2019 – May 9, 2019 · Past
Jake Bauer
Other companies: BridgeBio Oncology Therapeutics, Inc. (Director · Since at least Aug 11, 2025); Enliven Therapeutics, Inc. (Chairman of the Board of Directors · Since at least Feb 23, 2023)
Director · Since at least Apr 18, 2025
Mark S Levine
Other companies: 908 Devices Inc. (Chief Legal and Admin. Officer · Since at least Feb 26, 2026); Flexion Therapeutics Inc (General Counsel · Jan 5, 2021 – Nov 19, 2021 · Past)
Chief Legal Officer · Jan 19, 2022 – Nov 20, 2024 · Past
Naveen Yalamanchi
Other companies: Orchestra BioMed Holdings, Inc. (Chief Financial Officer, Director · Aug 3, 2020 – Aug 3, 2020 · Past); Rocket Pharmaceuticals, Inc. (Director · Jan 4, 2018 – Jun 13, 2024 · Past)
Vice President and CFO, Director · May 9, 2019 – May 9, 2019 · Past
Robert K Zeldin
Other companies: MeiraGTx Holdings plc (CHIEF MEDICAL OFFICER · Since at least Aug 3, 2020); Acceleron Pharma Inc (EVP & Chief Medical Officer · Jun 29, 2018 – Jan 25, 2019 · Past)
Chief Medical Officer · Dec 18, 2019 – Dec 18, 2019 · Past
Alice Lee
Other companies: Orchestra BioMed Holdings, Inc. (VP Operations, Sec & Treasurer · Aug 3, 2020 – Aug 4, 2020 · Past)
VPO, Secretary and Treasurer · May 9, 2019 – May 9, 2019 · Past
Douglas Hughes
Other companies: Eargo, Inc. (Director · Oct 15, 2020 – Nov 22, 2022 · Past)
Member of the Board of Directors · Since at least Dec 18, 2019
All 39 people
PersonSeat
Frank Torti
Other companies: Roivant Sciences Ltd. (President and Vant Chair · Since at least Jul 29, 2025)
Director · Since at least Apr 1, 2025
Frank Torti
Other companies: Roivant Sciences Ltd. (Vant Chair & President · Since at least May 20, 2026)
Executive Chairman · Since at least Apr 9, 2026
George Migausky
Other companies: Regenxbio Inc. (Chairman of the Board · Since at least May 31, 2024)
Director · Dec 1, 2023 – Apr 1, 2025 · Past
Jake Bauer
Other companies: BridgeBio Oncology Therapeutics, Inc. (Chairman · Since at least Aug 11, 2025)
Board Member · Since at least Apr 9, 2026
Jay S. Stout
Other companies: Aravive Inc (SVP, Technical Operations · Oct 6, 2017 – Apr 24, 2018 · Past)
Chief Technology Officer · Since at least Apr 17, 2023
Mark Schoenebaum
Other companies: TG Therapeutics, Inc. (Director · Apr 16, 2012 – Jun 26, 2018 · Past)
Director · May 9, 2019 – May 9, 2019 · Past
Melanie Gloria
Other companies: Acelyrin, Inc. (Chief Operating Officer · May 4, 2023 – May 23, 2024 · Past)
Chief Operating Officer · Since at least Nov 7, 2024
Stephanie A Sirota
Other companies: Orchestra BioMed Holdings, Inc. (VP of Corp Stratege and Comm · Aug 3, 2020 – Aug 4, 2020 · Past)
VP of CSC · May 9, 2019 – May 9, 2019 · Past
Aileen IlariaVice President, Clinical Operations – Global Site Management · Nov 4, 2026 – Nov 4, 2026 · Past
Andrew FromkinMember of the Board of Directors · Since at least May 29, 2026
Atul PandeDirector · Since at least Apr 1, 2025
Cassandra PauyoVice President, Data Management · Nov 4, 2026 – Nov 4, 2026 · Past
Chedvi Levin-SisterVice President of Finance · Since at least Nov 4, 2026
Christine BlodgettSenior Vice President of Human Resources · Since at least Nov 4, 2026
Christopher Van TuylChief Legal Officer and Corporate Secretary · Since at least Dec 16, 2024
Dawn GardnerVice President, Program Management · Since at least Nov 4, 2026
Elena GrigoryevaSenior Vice President, Head of Clinical Development · Since at least Nov 4, 2026
Eva Renee BarnettChief Financial Officer · Oct 4, 2021 – Apr 16, 2025 · Past
Harry BerlangaVP, CMC & Distribution Quality · Since at least Nov 4, 2026
Julia G ButchkoChief Development Officer · Dec 18, 2019 – Aug 21, 2024 · Past
Luciano PollastriniSenior Vice President, CMC Technical Operations · Nov 4, 2026 – Nov 4, 2026 · Past
Michael GeffnerChief Medical Officer · Since at least Jan 16, 2024
Philip TedeschiVice President, Translational Sciences and Clinical Laboratories · Since at least Nov 4, 2026
Robert SusmanDirector · Since at least Apr 18, 2025
Rod SaponjicVice President of Clinical Operations · Since at least Nov 4, 2026
Ruby GrewalChief Strategy Officer · Since at least Nov 4, 2026
Sheetal PatelSenior Vice President, Clinical Development · Since at least Nov 4, 2026
Tiago GirãoChief Financial Officer · Since at least May 29, 2025
Yan ZhengSenior Vice President Biostatistics, Programming & Data Management · Nov 4, 2026 – Nov 4, 2026 · Past

Open People

Log in to ask 6ix AI your own questions about Immunovant, Inc.